Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Total transaction value of the divestment is Rs. 3,660 million
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Subscribe To Our Newsletter & Stay Updated
